Research

Energy balance

There is a significant and growing public interest in Ozempic and related GLP-1 agonists.

Healthcare providers should be prepared for increased inquiries about these medications.

StrongSupportsmedium confidence
This study demonstrates a significant and growing public interest in Ozempic and related GLP-1 agonists.
Sabrina H. Han et al. · Aesthetic Surgery Journal · 2023

Why this rating

The claim is supported by data analysis over a significant time frame.

Source

Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis

Sabrina H. Han et al. · Aesthetic Surgery Journal · 2023

DOI 10.1093/asj/sjad211

otherCited 180×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →